Information Provided By: 
Fly News Breaks for September 23, 2016
ALXN
Sep 23, 2016 | 07:29 EDT
Jefferies analyst Eun Yang lowered her price target for Alexion Pharmaceuticals to $120 after conducting a survey of 35 U.S. hematologists/nephrologists. The survey results support a cautious outlook on Soliris sales in 2021 and beyond due to potential competition, Yang tells investors in a research note. Specifically, 60% of those surveyed will shift away from Soliris to biosimilars if they are available due to cost, Yang tells investors in a research note. The analyst keeps a Hold rating on Alexion.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
